title: Bupropion: congenital heart defects (continued).
abstract: Bupropion, an amphetamine, is authorised as an aid to smoking cessation, despite its negative harm-benefit balance. In 2004, data from a registry of pregnancies exposed to bupropion drew attention to an increased risk of congenital heart defects. In 2010, a case-control study including more than 10 000 children showed a higher incidence of in utero exposure to bupropion among children who had congenital left heart defects. Other, less reliable studies did not show such a link. In practice, this risk of congenital heart defects is yet another reason to avoid using bupropion, including during pregnancy, and to monitor the cardiac status of exposed fetuses and newborns.
mesh_terms: D016642:Bupropion / Q000009:adverse effects* / Q000627:therapeutic use; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D006330:Heart Defects, Congenital / Q000139:chemically induced* / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D016540:Smoking Cessation / Q000379:methods
chemical_list: D018765:Dopamine Uptake Inhibitors; D016642:Bupropion